"Vaccines, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
| Descriptor ID |
D014614
|
| MeSH Number(s) |
D12.776.828.868 D20.215.894.865 D23.050.865
|
| Concept/Terms |
Vaccines, Synthetic- Vaccines, Synthetic
- Synthetic Vaccines
- Synthetic Immunogens
- Immunogens, Synthetic
Molecular Vaccines- Molecular Vaccines
- Vaccines, Molecular
- Vaccines, Chemical
- Chemical Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Synthetic".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Synthetic".
This graph shows the total number of publications written about "Vaccines, Synthetic" by people in this website by year, and whether "Vaccines, Synthetic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 6 | 7 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Synthetic" by people in Profiles.
-
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2370087.
-
Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply. N Engl J Med. 2024 Mar 21; 390(12):1156.
-
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged =50 years in the United States. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2327145.
-
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023 Dec 14; 389(24):2245-2255.
-
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
-
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
-
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 Jul 19; 3(7):100679.
-
Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022 05 12; 386(19):1855-1857.
-
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
-
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 04 01; 5(4):e228879.